Home › Compound Library › Amlodipine (Norvasc)

Amlodipine (Norvasc)

Calcium Channel Blockerprescriptionoral · inferred

Long-acting calcium channel blocker for hypertension and angina. Its 30-50 hour half-life provides smooth 24-hour blood pressure control with once-daily dosing.

Projected serum levels — 5 mg, once daily

Amlodipine (Norvasc)
Amlodipine (Norvasc) modeled serum levels, 5 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 4 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 4
Amlodipine (Norvasc) modeled serum levels with a loading dose of 12.4 mg, then 5 mg once daily The first dose is larger so levels approach steady state faster. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 5 mg once daily (oral).

Loading schedule: 12.4 mg on day 1, then 5 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~4 days: peak ≈ 6.8 mg, trough ≈ 4.6 mg body load. Population-based estimate over 15 days for a 5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Calcium Channel Blocker
Route modeled
Oral
Model confidence
inferred
Half-life
35 h
Common dose
5 mg
Suggested maximum
10 mg/day
Reference dose range
2.5–10 mg (single dose)
Suggested cadence
once daily
Validated against
10 mg oral — Cmax 0.006 mg/L at 8 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Amlodipine (Norvasc) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Amlodipine (Norvasc) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Amlodipine (Norvasc) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~5.00x

  • contraindicated
    Diltiazem + Amlodipine (Norvasc) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Amlodipine (Norvasc) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Amlodipine (Norvasc) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~10.00x

Serum checks 260 modeled interaction pairings for amlodipine (norvasc) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly (ALLHAT) ALLHAT Officers and Coordinators · JAMA, 2002 DOI

    Largest hypertension trial (42,418 patients) found amlodipine provided similar cardiovascular protection to chlorthalidone, with superior stroke prevention.

  2. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required (ASCOT-BPLA) Dahlof B et al. · Lancet, 2005 DOI

    Major trial of 19,257 patients found amlodipine-based regimen was superior to atenolol-based regimen, reducing cardiovascular events by 16%, stroke by 23%, and all-cause mortality by 11%.

  3. Amlodipine, a once-daily calcium channel blocker: a review of its effects on blood pressure Murdoch D et al. · Drugs, 1991 DOI

    Comprehensive review establishing amlodipine as the first truly once-daily calcium channel blocker with smooth 24-hour blood pressure control and minimal reflex tachycardia.

3 published studies referenced in the app, each with a plain-language summary.